Nomura
http://www.nomura.com/Nomura (NYSE: NMR) is a global investment banking and securities firm. The firm’s operations include Domestic Retail, Global Markets, Global Investment Banking, Global Merchant Banking, and Asset Management. Nomura is headquartered in Tokyo, Japan.
Nomura is represented in the Americas by Nomura Holding America (NHA). NHA’s major divisions are Fixed Income, Investment Banking, Equities and Asset Management.
View Older Stories View More Recent Stories
-
Form 13F-NT NOMURA ASSET MANAGEMENT For: Sep 30
-
Form 13F-NT Nomura Asset Management For: Sep 30
-
Form 13F-HR/A NOMURA ASSET MANAGEMENT For: Sep 30
-
Form 13F-NT Nomura Asset Management For: Sep 30
-
Form 13F-HR NOMURA ASSET MANAGEMENT For: Sep 30
-
China reaffirms zero-COVID stance, city of Guangzhou on edge
-
Orchid Island Capital Announces November 2022 Monthly Dividend and October 31, 2022 Rmbs Portfolio Characteristics
-
Potentially divided U.S. government tees up tough economic debates for 2023
-
Vertical Aerospace Announces Third Quarter 2022 Financial Results
-
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022
-
Chinese property stocks soar on fresh regulatory support
-
China's factory gate prices suffer first drop since Dec 2020 as COVID curbs take toll
-
EA Licensed Esports Platform Realm Launches in Apex Legends
-
Form 6-K NOMURA HOLDINGS INC For: Nov 08
-
China's COVID epicentre shifts to Guangzhou as outbreaks widen
-
Form 6-K NOMURA HOLDINGS INC For: Nov 07
-
"MITSUKOSHI BGC," Commercial Facility by Isetan Mitsukoshi Holdings with Nomura Real Estate Development, Set for Soft Opening in Manila, Philippines on November 18
-
Banks raise Fed terminal rate forecasts after Powell's hawkish tone
-
CapLinked’s “Tasks” Help Dealmakers Close Deals
-
Form 6-K NOMURA HOLDINGS INC For: Nov 02
-
China vows commitment to growth as investors bet on easier COVID policy
-
Form 6-K NOMURA HOLDINGS INC For: Nov 02
-
Nomura calls quarterly profit unsatisfactory as market downturn bites
-
China vows commitment to growth as investors bet on easier COVID policy
-
HCA Healthcare to Present at November Healthcare Conferences
-
Mobileye Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
SPX Corp. (SPXC) Divests Legacy Asbestos Liabilities
-
SPX Technologies Divests Legacy Asbestos Liabilities
-
Orderly Network receives strategic investment from Laser Digital
-
Shanghai Disney visitors told to stay home after COVID case, Foxconn ups bonuses
-
Fed set to deliver another big rate hike, debate December downshift
-
Asia bond funds dump China in favour of cash after high-yield rout
-
China's factory, services activity skids on relentless COVID curbs
-
Japan unveils $200 billion in new spending to ease inflation pain
-
Shanghai food supplier's books reveal big profits under COVID lockdown
-
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
-
Orchid Island Capital Announces Third Quarter 2022 Results
-
Chinese cities double down on zero-COVID as outbreaks widen
-
Mobileye (MBLY) IPO Opens 27% Higher
-
Mobileye (MBLY) Prices 41M Share IPO at $21/sh
-
BOJ ramps up bond buying ahead of policy meet, yields fall sharply
-
Mobileye Announces Pricing of Initial Public Offering
-
Bill Hwang, Archegos demand end to SEC lawsuit over $36 billion firm's collapse
-
China's Q4 GDP hits early speed bump as COVID stifles economy
-
Japan Smaller Capitalization Fund, Inc. Announces Rescheduling of Annual Meeting of Shareholders
-
Myovant Sciences (MYOV) Acquired by Sumitomo Pharma for $27/sh or Company Value of $2.9B
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
-
China Q3 GDP growth tops forecasts but meaningful rebound elusive

